What was the market valuation of the Spain hematopoietic stem-cell-transplantation market in 2024?

The market valuation was $105.93 Million in 2024. Read More

What is the projected market valuation for the Spain hematopoietic stem-cell-transplantation market by 2035?

The projected valuation for 2035 is $258.89 Million. Read More

Which companies are considered key players in the Spain hematopoietic stem-cell-transplantation market?

Key players include Novartis, Bristol-Myers Squibb, Amgen, Gilead Sciences, Celgene, Takeda Pharmaceutical, Roche, Merck & Co., and AstraZeneca. Read More

What are the two main types of transplants in the Spain hematopoietic stem-cell-transplantation market?

The two main types of transplants are allogeneic and autologous. Read More

What were the market values for allogeneic and autologous transplants in 2024?

In 2024, allogeneic transplants were valued at $45.0 Million, while autologous transplants were valued at $60.93 Million. Read More

What was the market value for Non-Hodgkin Lymphoma in 2024?

The market value for Non-Hodgkin Lymphoma in 2024 was $25.0 Million. Read More

What were the market values for Bone Marrow Transplant and Peripheral Blood Stem Cells Transplant in 2024?

In 2024, Bone Marrow Transplant was valued at $35.0 Million, while Peripheral Blood Stem Cells Transplant was valued at $40.0 Million. Read More

Spain Hematopoietic Stem Cell Transplantation Market

Q: What is the expected CAGR for the Spain hematopoietic stem-cell-transplantation market during the forecast period 2025 - 2035?

The expected CAGR during this period is 8.46%. Read More

Q: What indications are covered in the Spain hematopoietic stem-cell-transplantation market?

Indications include Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Other Non-Malignant Disorders. Read More

Q: What applications are included in the Spain hematopoietic stem-cell-transplantation market?

Applications include Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, and Cord Blood Transplant. Read More

Spain Hematopoietic Stem Cell Transplantation Market Research Report By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders) and By Application (Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, Cord Blood Transplant) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

8.46%

2024 Market Size

$ 105.93 Million

2035 Market Size

$ 258.89 Million

Life Sciences ● Updated August 2026 Report ID: MRFR/LS/48286-HCR | Pages: 200 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Transplant Type (USD Million)
  1. 4.1.1 Allogeneic
  2. 4.1.2 Autologous
2. 4.2 Construction, BY Indication (USD Million)
  1. 4.2.1 Acute Myeloid Leukemia
  2. 4.2.2 Acute Lymphoblastic Leukemia
  3. 4.2.3 Hodgkin Lymphoma
  4. 4.2.4 Non-Hodgkin Lymphoma
  5. 4.2.5 Multiple Myeloma
  6. 4.2.6 Other Non-Malignant Disorders
3. 4.3 Construction, BY Application (USD Million)
  1. 4.3.1 Bone Marrow Transplant
  2. 4.3.2 Peripheral Blood Stem Cells Transplant
  3. 4.3.3 Cord Blood Transplant
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Celgene (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Takeda Pharmaceutical (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SPAIN MARKET ANALYSIS BY TRANSPLANT TYPE
3. 6.3 SPAIN MARKET ANALYSIS BY INDICATION
4. 6.4 SPAIN MARKET ANALYSIS BY APPLICATION
5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CONSTRUCTION
8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
11. 6.11 CONSTRUCTION, BY TRANSPLANT TYPE, 2024 (% SHARE)
12. 6.12 CONSTRUCTION, BY TRANSPLANT TYPE, 2024 TO 2035 (USD Million)
13. 6.13 CONSTRUCTION, BY INDICATION, 2024 (% SHARE)
14. 6.14 CONSTRUCTION, BY INDICATION, 2024 TO 2035 (USD Million)
15. 6.15 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
16. 6.16 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TRANSPLANT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Spain Hematopoietic Stem Cell Transplantation Market Segmentation

Spain Hematopoietic Stem Cell Transplantation Market By Transplant Type (USD Million, 2025-2035)

Allogeneic
Autologous

Spain Hematopoietic Stem Cell Transplantation Market By Indication (USD Million, 2025-2035)

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Multiple Myeloma
Other Non-Malignant Disorders

Spain Hematopoietic Stem Cell Transplantation Market By Application (USD Million, 2025-2035)

Bone Marrow Transplant
Peripheral Blood Stem Cells Transplant
Cord Blood Transplant

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”